<DOC>
	<DOCNO>NCT00653250</DOCNO>
	<brief_summary>RATIONALE : Studying sample tissue , blood , urine patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . PURPOSE : This clinical trial study celecoxib treat patient stage I , stage II , stage IIIA non-small cell lung cancer .</brief_summary>
	<brief_title>Celecoxib Treating Patients With Stage I , Stage II , Stage IIIA Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To assess cyclo-oxygenase-2 ( COX-2 ) activity patient early-stage non-small cell lung cancer ( NSCLC ) correlate result serum vascular endothelial growth factor ( VEGF ) level , tumor microvessel density score , tumor prostaglandin E2 ( PGE_2 ) matrix metalloproteinases ( MMP ) level , major urinary metabolite PGE_2 , PGE-M. - To assess effect specific COX-2 inhibitor ( celecoxib ) COX-2 expression within primary tumor , serum VEGF level tumor microvascular density , tumor PGE_2 MMP level , urinary PGE-M cohort patient early-stage NSCLC . OUTLINE : Patients receive oral celecoxib 400 mg twice day 5 day absence disease progression unaccepted toxicity . Patients early-stage disease undergo surgery . Biopsy , serum , urine sample obtain baseline celecoxib treatment . The biopsy specimen examine expression cyclo-oxygenase-2 ( COX-2 ) , PGE_2 , select MMPs immunohistochemistry , western blotting , northern blotting . Serum urine sample analyze VEGF PGE-M expression . COX-2 tumor expression correlate serum VEGF level ; tumor MMP-2 , MMP-9 , PGE_2 expression ; urinary PGE-M microvessel density score .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Presumed histological cytological diagnosis nonsmall cell lung cancer Diagnosis confirm upon study entry collect biopsy material correlative study Stage IIIIA disease PATIENT CHARACTERISTICS : ECOG performance status 02 Serum creatinine ≤ 1.5 mg/dL Granulocytes ≥ 1,500/mm^3 Platelets ≥ 100,000/mm^3 AST ≤ 3 time normal Bilirubin ≤ 1.5 mg/dL Not pregnant nursing Fertile patient must use effective contraception No active unresolved infection PRIOR CONCURRENT THERAPY : At least 7 day since prior concurrent nonsteroidal antiinflammatory agent cyclooxygenase2 inhibitor At least 7 day since prior parenteral antibiotic No prior systemic chemotherapy radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
</DOC>